Featured Articles

Asceneuron SA announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ASN120290 for the treatment of progressive supranuclear palsy (PSP), a…
Read More...

BioNTech AG and Genevant Sciences announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need. The…
Read More...

Selexis SA announced that under the terms of an earlier commercial license agreement, Symphogen A/S has opened two investigational new drug applications (INDs) for clinical programs…
Read More...

SRI International announced a research agreement with Ionis Pharmaceuticals, combining SRI's proprietary FOX Three Molecular Guidance cellular targeting system (MGS) with Ionis'…
Read More...

Mylan announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' Exelon Patch. Mylan received final…
Read More...

MabVax Therapeutics Holdings and Boehringer Ingelheim announced they have signed an asset acquisition and related agreements centered on MabVax's program targeting a glycan commonly…
Read More...

Belgium-based global bio-pharmaceutical company UCB announced it has received an Import Drug License (IDL) from the China Food and Drug Administration (CFDA), creating a pathway to make…
Read More...

Sorrento Therapeutics announced that it acquired the Sofusa lymphatic delivery technology platform from Kimberly-Clark Corporation for targeted biopharmaceuticals, particularly, the…
Read More...

Treating advanced breast cancer with three drugs instead of one could boost the effectiveness of treatment and stop tumours developing resistance, a new study reports. Researchers…
Read More...

Recipharm has announced the launch of its standalone serialisation service ahead of the introduction of the EU Falsified Medicines Directive (FMD). The new service is designed to…
Read More...

AbbVie and Calibr announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors. This collaboration broadens AbbVie's oncology research to…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for baloxavir marboxil as a single-dose, oral…
Read More...

Aquinox Pharmaceuticals announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain…
Read More...

Sanofi and Ablynx announced today that Sanofi has now acquired all outstanding shares (including shares represented by American Depositary Shares (“ADSs”)), warrants and convertible…
Read More...

Merck announced that it has entered into an agreement with HistoCyte Laboratories Ltd, Tyne, U.K., to be the exclusive multinational distributor of the company’s portfolio of cell line…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published positive…
Read More...

Asterias Biotherapeutics announced enrollment and dosing of the first subject in the first-in-human Phase 1 clinical trial of AST-VAC2 in the United Kingdom. This initial clinical…
Read More...

Thermo Fisher Scientific Inc. officially opened its U.S. Precision Medicine Science Center (PMSC) in Cambridge, Mass. The Center offers access to advanced "omics" technologies and…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a…
Read More...

GE Healthcare will provide Xiangxue Pharmaceutical Co., Ltd. (XPH) with a FlexFactory for cell therapy, a semi-automated end-to-end manufacturing platform, to help scale up, digitize…
Read More...